TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PPI and Clopidogrel Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers aged between 18 and 75 years~Exclusion Criteria:~1. Known allergies to clopidogrel or omeprazole.~2. Blood dyscrasia or bleeding diathesis.~3. Recent antiplatelet treatment (\< 30 days) with a glycoprotein IIb/IIIa antagonist, thienopyridine (ticlopidine, clopidogrel), cilostazol or dipyridamole.~4. Treatment with other medications that may interfere with the CYP system (ketoconazole, itraconazole, diltiazem, erythromycin, clarithromycin, fluvoxamine, fluoxetine, nefazodone, or sertraline).~5. Platelet count \<100x106/microL.~6. Diabetes mellitus~7. History of coronary artery disease, gastrointestinal bleed, gastroesophageal reflux disease (GERD), cerebrovascular event or any active malignancy.~8. Active bleeding or hemodynamic instability.~9. Serum creatinine \>2mg/dL.~10. Baseline ALT \>2.5 times the upper limit of normal.~11. Pregnant females.~12. Patients taking omeprazole or any H2 antagonist or proton pump inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Omeprazole (Type: ACTIVE_COMPARATOR): prospective, open-label, two-sequence, three-period, randomized crossover study
- Pantoprazole (Type: ACTIVE_COMPARATOR): prospective, open-label, two-sequence, three-period, randomized crossover study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Written informed consent~* Confirmed diagnosis of cystic fibrosis~* Aged \> 6 years~* FEV1 \>30 % and \< 90% predicted~* Able to perform all the techniques necessary to measure lung function~Main Exclusion Criteria:~* Terminally ill or listed for lung transplantation~* Had a lung transplant~* Using nebulised hypertonic saline~* Significant episode of haemoptysis (\>60 mL) in the three months prior to enrolment~* Recent myocardial infarction or cerebral vascular accident~* Breast feeding or pregnant, or plan to become pregnant while in the study participating in another investigative drug study, parallel to, or within 4 weeks of study entry~* Allergy or intolerance to mannitol~* Using beta blockers~* Have a condition or be in a situation which in the Investigator's opinion may put the subject at significant risk, may confound results or may interfere significantly with the patient's participation in the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of the Passy Muir Swallowing Self Trainer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 13 years or older~* Stable medical condition~* Diagnosed with oropharyngeal dysphagia confirmed by Modified Barium Swallow (MBS) baseline measure of the follow two scales:~  1. Penetration-Aspiration Scale score of 2 or greater verified by modified barium swallow (Rosenbek et al., 1996) and/or~ 2. Functional Oral Intake Scale score of 5 or lower (Crary et al., 2005)~* Folstein Mini-Mental State Examination (MMSE) score of 23 or greater indicating cognitive ability to follow directions and communicate preferences~* Willingness to travel to Sentara Rockingham Memorial Hospital 2 or more times to undergo initial evaluation, device use training and checkup at 3 months.~Exclusion Criteria:~* Pregnancy~* Cardiac problems~  * history of cardiac rhythm condition (including heart murmur or cardiac arrhythmia)~ * cardiac pacemaker in place~* Highly-pigmented (dark) skin color is an exclusion criterion because near-infrared spectroscopy requires the measurement of the degree of absorption of different wavelengths of light after being reflected back through the scalp. Highly pigmented skin interferes with wavelength transmission, making the measurement of changes in absorption inaccurate.~* Lack of a primary care physician who can be contacted if there are findings on the Magnetic Resonance Imaging (MRI) scan.~* Presence of metal in the body (prostheses, electrodes, shrapnel, aneurism clips, other medical hardware)~* Presence of certain tattoos with ferromagnetic metal or permanent makeup, due to the exposure to high magnetic force through MRI procedures.~* Subjects who were metal workers as a previous occupation will also be excluded due to the possibility of unknown/undetected metal in their body.~* Volunteers with broken skin in the area that the functional Near Infra-Red Spectroscopy (fNIRS) probes will be placed on the scalp~* Claustrophobia~* Previous surgery that used surgical staples~* Artificial joints

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Dysphagia retraining with device (Type: None): Participants with dysphagia received baseline testing of dysphagia and dysphagia handicap. Then received training on how to use a vibrotactile device for self training at home. They used the device for 3 months and returned for re-evaluation on testing of dysphagia and feedback on the device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult PLWA 18 and older, with a clinical diagnosis of symptomatic bilateral LE PN will be invited to participate.~* The participants will be on a stable pain and HIV/AIDS management regimen without foreseeable alterations or changes to said pharmacological regimen, which may include pain and or sleep medications.~* The participants will be community dwelling individuals, able to walk at or above a modified independence level with or without the need of an assistive device to ambulate, such as a cane or walker.~* Eligible participants will report at least one of the following clinical symptoms: paresthesia, dysesthesia, and report night cramps in the LE~Exclusion Criteria:~* Participants will be excluded if they have a clinical diagnosis of any of the following: significant cardiovascular or pulmonary disease (specifically, myocardial infarction within the past six months, angina, or dyspnea at rest), paraplegia, hemiplegia, other major neurological dysfunction, diabetes, absent pedal pulse during examination, sleep apnea, or are pregnant.~* Additionally, patients unable to read English, patients with changes to their pharmacological management during the study and or using any mechanical devices to assist in normalizing sleep will be excluded from this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Splinting application (Type: EXPERIMENTAL): Participants will be asked to wear a pair of LE night splints for the duration of the study (6 weeks) at night/during sleep only.
- Splint liner application (Type: PLACEBO_COMPARATOR): The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* In female subjects either childbearing potential terminated by surgery or one year post-menopausal, or a negative serum pregnancy test during screening and the willingness not to become pregnant during the study period and 30 days after the last vaccination by practicing reliable methods of contraception~* Written informed consent obtained prior to study entry~Exclusion Criteria:~* History of clinical manifestation of any flavivirus infection~* History of vaccination against Japanese encephalitis (JE), Yellow fever and Dengue fever (an anti-JEV neutralizing antibody titer \>= 1:10 at baseline is acceptable for inclusion, these subjects will be part of the safety population, but will not be analyzed for immunogenicity in the per-protocol analysis)~* History of any previous Hepatitis A vaccination and infection~* Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine~* Planned administration of another vaccine during the study period~* Immunodeficiency including post-organ-transplantation or immunosuppressive therapy~* A family history of congenital or hereditary immunodeficiency~* History of autoimmune disease~* Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within six months of vaccination.~* Any acute infections within 4 weeks prior to enrollment~* Infection with human immunodeficiency virus (HIV), Hepatitis B (HBsAg) or Hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- IC51 and Placebo (Type: ACTIVE_COMPARATOR): 6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)
- HAVRIX and placebo (Type: ACTIVE_COMPARATOR): HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)
- IC51 and HAVRIX (Type: ACTIVE_COMPARATOR): IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of type 2 diabetes~* Participants between the ages of 30 and 80~Exclusion Criteria:~1. Presence of type 1 diabetes~2. Presence of renal insufficiency or pulmonary disease~3. Presence of clinically significant neuropathy that is clearly of non-diabetic origin~4. Amputations of lower extremities or presence of foot ulcers~5. Major macrovascular events such as myocardial infarction or stroke within the past 3 months~6. Uncontrolled or untreated hypothyroidism~7. Abnormalities of liver function defined as any liver enzymes (AST, ALT, SGPT, SGOT) greater than 3 times the upper limit of normal~8. Other serious medical conditions which, in the opinion of the investigator, would compromise the subject's participation in the study~9. Stable use (\> 3 months) of antioxidant supplements or drugs known to affect oxidative stress and PDN~10. Allergy to oxybutynin or other ingredients in Gelnique 3%~11. Pregnancy or breastfeeding~13) History of alcohol abuse in the last year 14) Urinary retention or an enlarged prostate 15) Uncontrolled glaucoma 16) Gastric retention or gastroparesis (hard to digest food) 17) Currently taking other medicines to treat overactive bladder (Anticholinergics)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 3% oxybutynin (Type: ACTIVE_COMPARATOR): Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the active drug arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
- Placebo (Type: PLACEBO_COMPARATOR): Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the placebo group arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent~* Men or women 18 years of age or older~* Current diagnosis of a recurrence of non-severe, non-complicated CDI~* Subject has a clinical response to standard-of-care CDI antibiotics for the most recent CDI episode~Exclusion Criteria:~* Pregnant, breast-feeding, or considering becoming pregnant during the study~* Prior history, evidence, or diagnosis of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis)~* Any prior diagnosis of diarrhea-predominant irritable bowel syndrome~* Systemic chemotherapy or radiation for the treatment of cancer during the 60 days prior to consent or planned during the 8 weeks following Randomization~* Prior fecal transplant for any condition, regardless of route of administration in the last year or plans to undergo during the study~* Major intra-abdominal surgery within the past 60 days prior to Screening~* History of total colectomy/ileostomy or bariatric surgery~* Admitted to, or expected to be admitted to an intensive care unit for any medical reason. Note: Residents of long term care facilities are eligible study entry~* Planned hospitalization or invasive surgery during the study~* Severe acute illness unrelated to CDI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CP101 (Type: EXPERIMENTAL): Full Spectrum Microbiota Capsule
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo Capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria: Healthy Volunteers~1. Male and females 21-65 years.~2. Clinically acceptable medical history~Key Exclusion Criteria: Healthy Volunteers~1. Received ionising radiation exposure from clinical trials or medical examinations or treatment in the last 12 months.~2. Suffers from claustrophobia.~3. Bilateral hip prostheses.~Key Inclusion Criteria: Patients~1. Male 18-80 years.~2. Histologically confirmed adenocarcinoma of the prostate~3. Clinically acceptable medical history~4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2~Key Exclusion Criteria: Patients~1. Biopsy 28 days prior to enrollment.~2. Extensive metastatic disease.~3. Underlying disease which might confound interpretation.~4. Bilateral hip prostheses.~5. High energy (\>300 Kiloelectron Volt (keV)) gamma-emitting radioisotope administered within five physical half-lives, or any intravenous iodinated contrast medium within 24 hours, or any high density oral contrast medium (oral water contrast is acceptable) within 5 days prior to study drug administration.~6. X-ray contrast agent (\<24 hr for intravenous agents and \<5 days for oral agents).~7. History of claustrophobia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Volunteers (Type: EXPERIMENTAL): Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
- Patients (Type: EXPERIMENTAL): Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. .endoscopy and biopsy verified rectal cancer within 12cm from anal verge;~2. .primary MRI, TRUS, abdomino-chest CT diagnosed early or intermediate or bad Stage II/III rectal cancer;~3. .age from 20-75;~4. .with informed consent;~Exclusion Criteria:~1. .refuse the further treatment after recruiting;~2. .diagnosis of peritoneal metastasis in the surgery;

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- chemotherapy group (Type: EXPERIMENTAL): patients receive 4 cycles of Xelox

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Caucasian~* Body Mass Index (BMI) between 18 and 27 kg/m\^2, both inclusive~* Good health as indicated by medical history, physical examination including vital signs and ECG, and clinical laboratory test results~* Smoke less than 10 cigarettes (or equivalent) per day~* Capable of giving written Informed Consent (IC)~Exclusion Criteria:~* Evidence of clinically relevant pathology or potential thromboembolic risk based on medical and/or family history as judged by the Investigator~* Known history of atherosclerosis, arteriosclerosis, thromboembolic events or known high levels of Troponin I~* Known or suspected allergy to activated recombinant human factor VII or related products or any of the components of the formulation~* Overt bleeding, including from gastrointestinal tract~* Hepatitis (B or C) infection~* HIV (human immunodeficiency virus) infection

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- CP-rFVIIa (Type: ACTIVE_COMPARATOR): None
- VII25 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for Mothers:~* HIV infected~* Pregnant with a viable fetus~* Between 28 and 38 weeks of pregnancy~* CD4 count greater than 250 cells/mm3 within 30 days prior to study entry~* Able to receive oral ART during labor~* Willing to use acceptable forms of contraception while on study treatment~* Able to provide written informed consent~Exclusion Criteria for Mothers:~* Known allergy or hypersensitivity to ddI, LPV, NVP, ritonavir (RTV), or ZDV~* Any ART other than ZDV during a previous pregnancy or the current pregnancy~* Certain medications~* Planning to receive additional ART during the first 8 weeks postpartum~* Planning to breastfeed~* Unlikely to comply with postpartum study requirements, in the opinion of the investigator~* Certain abnormal laboratory values within 30 days prior to study entry

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: LPV/r x 7d (Type: EXPERIMENTAL): NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and BID for 7 days postpartum, ddI 250 mg orally daily (if body weight \<60 kg) or 400 mg orally twice daily (if body weight \>= 60 kg) at the onset of labor, during labor, and for 7 days postpartum, LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 7 days postpartum.
- Arm B: no LPV/r (Type: EXPERIMENTAL): NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight \<60 kg) or 400 mg orally daily (if body weight \>= 60 kg) at the onset of labor, during labor, and for 30 days postpartum.
- Arm C: LPV/r x 30d (Type: EXPERIMENTAL): NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight \<60 kg) or 400 mg orally daily (if body weight \>= 60 kg) at the onset of labor, during labor, and for 30 days postpartum,LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 30 days postpartum.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete